sarepta therapeutics arrowhead news - Search News

Arrowhead climbs

Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal

Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta Therapeutics. TransMedics Group's (NASDAQ:TMDX) investors will be pleased with their massive 349% return over the last five years The Stock ...

YAHOO!Finance · 1h

Sarepta to pay Arrowhead $500M + in licensing deal for siRNA-based treatments

Sarepta Therapeutics (SRPT), the leader in precision genetic medicine for rare diseases announced an exclusive global licensing and collaboration agreement with Arrowhead (ARWR) Pharmaceuticals ( ARWR).

Seeking Alpha on MSN · 1d

Arrowhead climbs after licensing deal with Sarepta

Arrowhead Pharmaceuticals (NASDAQ:ARWR) added ~21% in the premarket on Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ:SRPT) for various clinical and preclinical programs.

Sarepta, Arrowhead Pharmaceuticals partner to advance RNA-based drugs in rare diseases

Sarepta Therapeutics said Tuesday that it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of ...

14h

Sarepta Therapeutics’ Strategic Partnership with Arrowhead Signals Strong Growth Prospects: A Buy Recommendation

Analyst Kostas Biliouris of BMO Capital reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of ...

Rx Rundown: Roche, Sarepta Therapeutics, Merck and more

Roche acquired cell therapy maker Poseida Therapeutics in a $1.5 billion deal. Sarepta Therapeutics and Arrowhead ...

20h

Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results